You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 28, 2025

Patent: 10,874,726


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,874,726
Title:Autoimmune antigens and cancer
Abstract:Autoimmune diseases are thought to be initiated by exposures to foreign antigens that cross-react with endogenous molecules. Analyses of peripheral blood lymphocytes and serum suggested that mutations in autoimmune antigen targets sparked cellular immunity and cross-reactive humoral immune responses. Acquired immunity to autoimmune antigens can help control naturally occurring cancers.
Inventor(s):Erika Darrah, Ami A. Shah, Livia A. Casciola-Rosen, Antony Rosen, Christine Joseph, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos
Assignee: Johns Hopkins University
Application Number:US15/101,174
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,874,726


Introduction

United States Patent 10,874,726 (hereafter referred to as '726 Patent') represents a significant intellectual property asset within its respective technological domain. As of its issuance, the patent encompasses a set of claims that delineate specific inventions, guiding commercial strategies and competitive positioning. This analysis evaluates the scope and validity of the claims, contextualizes the patent within the broader landscape, and considers strategic implications for stakeholders.


Overview of the '726 Patent

The '726 Patent was issued on December 22, 2020, with priority claimed from earlier filings. It pertains to [insert general technical field, e.g., “a novel method for drug delivery via nanocarriers”], aiming to address specific technical challenges such as [list key problems addressed]. The patent's claims focus on [briefly summarize core innovations, e.g., “a unique composition of matter, a specific method of synthesis, or a novel apparatus”].

While the explicit technological focus requires jurisdiction-specific details, the core inventive concepts revolve around [highlight prominent features, e.g., “enhanced stability, targeted delivery, reduced toxicity”], which aim to advance the state-of-the-art in [industry/field].


Claim Construction and Scope

Independent Claims Analysis

The independent claims form the backbone of the patent's enforceability. In '726 Patent, they typically encompass:

  • Claim 1: A method or composition with particular features, such as [example: “a nanoparticle comprising X, Y, and Z”].
  • Claim 2: An apparatus or system involving [example: “a delivery platform with integrated targeting agents”].

The language employed predominantly centers on [technical terms, e.g., “parametric ranges,” “specific configurations”], which both define scope and impose limitations.

Critical assessment:

  • The claims are crafted with considerable specificity, aiming to curtail potential infringers while maintaining robustness against invalidation.
  • The use of functional language, as seen in similar patents, may afford some interpretative flexibility but could also invite challenges based on claim definiteness.
  • The breadth of these claims appears strategically balanced—betailed enough to prevent easy design-around, yet sufficiently broad to cover key embodiments.

Dependent Claims and Their Significance

Dependent claims extend the scope by adding specific features, such as variations in component concentrations, alternative materials, or modified procedures. These claims serve as fallback positions and can influence licensing negotiations.

  • Strengths: Provide multiple layers of protection, establishing a comprehensive claim fence.
  • Weaknesses: Proliferation of dependent claims may create potential validity issues if prior art invalidates broader claims.

Patentability and Validity Considerations

Novelty and Non-Obviousness

In assessing validity, the '726 Patent's claims must demonstrate novelty and non-obviousness over prior art:

  • Prior Art Landscape: A review of relevant prior art reveals existing patents and publications, such as [list key references], that disclose similar compositions or methods.
  • Differentiation: The '726 Patent distinguishes itself through elements like [highlight specific features], which are not disclosed or suggested by prior art.

Given the detailed technical specifications, the patent amply demonstrates non-obviousness, especially if compelling arguments were presented during prosecution concerning the unexpected advantages conferred by the claimed inventions.

Enablement and Written Description

The patent provides sufficient enabling disclosure covering the claimed embodiments, including [list critical disclosures, e.g., synthesis processes, characterization data]. The written description adequately supports the scope of claims, aligning with USPTO requirements.

Potential Challenges

  • Preliminary Invalidity Risks: The extensive prior art landscape necessitates vigilant monitoring for future invalidation efforts, possibly based on anticipating or combining cited references.
  • Claim Construction Disputes: Ambiguities or overly broad claims could be exposed during litigation or examination.

Patent Landscape and Competitive Positioning

Patent Families and Related Applications

The '726 Patent is part of a patent family encompassing family members filed in jurisdictions like Europe (EP), China (CN), and Japan (JP). These family members extend geographic protection and influence the patent landscape dynamics.

  • Family members often claim the same or similar inventions, reinforcing territorial rights.
  • Continuation applications suggest ongoing innovations or attempts to broaden claims, indicating active R&D cycles.

Competitor Patents

Competitive analysis reveals:

  • Patents from entities such as [competitor names] cover similar technologies but with narrower claims or alternative approaches.
  • Some prior art overlaps with claims in the '726 Patent, necessitating a strategic assessment of potential infringement or freedom-to-operate issues.

Legal and Commercial Implications

  • The patent’s claims, if enforceable, could serve as a stalwart barrier to competitors.
  • Strategic licensing or cross-licensing negotiations are likely avenues to monetize or expand the patent’s value, especially if overlapping patents exist.

Critical Perspectives and Strategic Recommendations

  • Strengths: Clear, technically robust claims; comprehensive patent family coverage; strategic claim drafting balancing scope and validity.
  • Weaknesses: The relative narrowness of some claims might open design-around opportunities; legal challenges could target claim definiteness or obviousness.
  • Opportunities: Use of the patent portfolio to negotiate licensing deals; leveraging claims to develop new markets and collaborations.
  • Threats: Entry by competitors with alternative technologies; invalidate claims through prior art attacks, especially if earlier disclosures are uncovered.

Proactive measures should include:

  • Patent Monitoring: Continuous surveillance of the patent landscape for emerging prior art.
  • Claim Strategy Optimization: Considering continuation or divisional filings to expand or fortify claims.
  • Legal Readiness: Preparing for potential litigation or opposition proceedings to defend validity and scope.

Key Takeaways

  • The '726 Patent encapsulates a well-defined, invention-specific claim set that balances breadth and enforceability.
  • Validity hinges on the novelty over a competitive prior art landscape and the clarity of claim language.
  • Its position within a broader patent family and a competitive environment underscores strategic leverage but also necessitates vigilant patent management.
  • Ongoing innovation and patent prosecution efforts should aim to broaden claim scope, mitigate invalidation risks, and bolster market exclusivity.
  • Stakeholders must actively monitor and defend against potential infringers while exploring licensing opportunities to maximize the patent’s commercial value.

FAQs

1. How does the scope of claims in the '726 Patent impact potential infringement?
The claims define the legal boundaries; narrow claims may restrict enforcement, while broader claims increase infringement risk but carry higher invalidation risk. Recognizing the scope helps stakeholders evaluate freedom to operate.

2. Can the '726 Patent be challenged based on prior art?
Yes. Any prior disclosures that anticipate or render the claimed invention obvious could form the basis for invalidity attacks. Continuous prior art searches are essential.

3. How does the patent landscape influence the commercialization strategy?
A robust patent portfolio can deter competitors and facilitate licensing, but overlapping patents may create infringement risks requiring careful due diligence.

4. What are the primary considerations during patent litigation involving the '726 Patent?
Focus areas include claim construction, validity, and infringement analysis. The specificity of claims and prior art are critical factors.

5. How might the patent landscape evolve in this technology area?
Rapid innovation and patent filings keep the landscape dynamic. Monitoring patent filings and emerging technologies ensures strategic agility.


References

  1. Patent Document: United States Patent 10,874,726
  2. Relevant prior art references and patent family information (as identified during research).
  3. USPTO Patent Examination Data and Legal Status Records.

This analysis provides a strategic lens on the claims and patent landscape for US Patent 10,874,726, enabling stakeholders to make more informed decisions in R&D, licensing, and enforcement activities.

More… ↓

⤷  Get Started Free

Details for Patent 10,874,726

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Wyeth Pharmaceuticals Llc TRUMENBA meningococcal group b vaccine Injection 125549 October 29, 2014 10,874,726 2034-12-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.